thought call
held serv report beat reaffirm guidanc essenti in-lin
large-cap biopharma peer prettiest result benefit lower
opex mix result across number key product think still set
compani beat guidanc specif prolia xgeva enbrel miss
though next gener growth asset otezla repatha biosimilar
strong inde expect look continu headwind
prolia xgeva otezla strength remain posit compani
pipelin catalyst think combin near-term enbrel ip litig
competit remain overhang ahead tezepelumab
omecamtiv read-out think offer better risk reward street
expect order drive differenti growth rel peer believ
need see asset de-risk later year increas pt
maintain equal weight rate
strong pipelin catalyst calendar intact note think
critic piec narr compani next set pipelin driver
tezepelumab omecamtiv set read-out reaffirm
timelin critic importantli view updat phase data
close scrutin otezla data mild-to-moder psoriasi
repres good expans opportun product particularli ahead
competitor data
adjust estim base result recent trend adjust
estim reflect impact product-specif dynam net
impact chang bring ep
quarterli annual ep usd
rais usd
return equiti ttm
idc link barclay live interact chart
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight otezla acquisit
boost/reset top-lin growth face
erod base busi still fall biopharma
peer late-stag pipelin
intrigu -- key dataset weight
tezepelumab/omecamtiv increas
competit across kra see limit room
out-performance base/legaci franchis
overcom much biosimilar/gener concern
posit clinic win omecamtiv
stop earli success acceler time-to-market
potenti franchis clinically-
downsid case reflect acceler biosimilar
eros advers court decis otezla
patent neg clinic data across one
later-stag program omecamtiv tezepelumab
chang model
base result recent trend adjust estim reflect impact
product-specif dynam net impact chang bring
ep
new price target prior base npv sum-of-the-part analysi
compris commercial-stag portfolio biosimilar prior
pipelin net cash inclus beigen stake prior
appli tax rate discount rate
mn except per share datanewpriornewpriornewpriortot gross total oper interest pre-tax tax expens non-gaap net non-gaap ep dilut share outstand barclay inc
carter gould herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
procedur pleas
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
unless otherwis indic price sourc bloomberg reflect close price relev trade market may
last avail price time public
barclay bank plc and/or affili lead manag co-lead manag publicli disclos offer secur issuer
 employe non-execut director barclay plc director issuer
cd barclay bank plc and/or affili market-mak debt secur issu issuer
ce barclay bank plc and/or affili market-mak equiti secur issu issuer
barclay bank plc and/or affili receiv compens invest bank servic issuer past month
 barclay bank plc and/or affili expect receiv intend seek compens invest bank servic issuer
within next month
fa barclay bank plc and/or affili benefici own class equiti secur issuer calcul accord
us regul
fb barclay bank plc and/or affili benefici own long posit class equiti secur issuer
calcul accord eu regul
fc barclay bank plc and/or affili benefici own short posit class equiti secur issuer
calcul accord eu regul
fd barclay bank plc and/or affili benefici own class equiti secur issuer calcul accord
south korean regul
gd one research analyst fundament credit coverag team and/or member household long posit
common equiti secur issuer
ge one research analyst fundament equiti coverag team and/or member household long posit
common equiti secur issuer
 issuer benefici own class common equiti secur barclay plc
barclay bank plc and/or affili parti agreement issuer provis financi servic barclay bank plc and/or
affili
 barclay bank plc and/or affili liquid provid and/or trade regularli secur issuer and/or relat
